
Quarterly report 2022-Q4
added 02-09-2023
Quotient Limited Cash Flow 2011-2026 | QTNT
Annual Cash Flow Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-77.6 M | -80.6 M | -75.7 M | -68.4 M | -56.2 M | - | - | - | - | - | - |
Depreciation & Amortization |
8.8 M | 12.5 M | 12.7 M | 10.3 M | 9.38 M | 2.86 M | 1.18 M | 519 K | 337 K | - | - |
Accounts Payables |
4.66 M | 4.83 M | 5.94 M | 5.44 M | 10.8 M | 7.29 M | 7.24 M | - | - | - | - |
Accounts Receivables |
5.32 M | 5.4 M | 3.35 M | 2.86 M | 2.56 M | 2.27 M | 1.81 M | - | - | - | - |
Total Inventories |
22 M | 20.5 M | 15.6 M | 16.3 M | 13.6 M | 12.6 M | 4.61 M | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -89.2 M | -64.3 M | - | - | -96.2 M | -58.7 M | -32.1 M | - | -56.7 M | -30.6 M | -24.8 M | - | -64.8 M | -42.7 M | -25.1 M | - | -61.5 M | -41.1 M | - | - | - | -19.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
- | - | - | - | - | - | - | - | 2.34 M | 6.43 M | 4.09 M | - | 2.9 M | 9 M | 6.07 M | 3.01 M | 3.06 M | 9.5 M | 6.42 M | - | 2.58 M | 2.59 M | 2.46 M | - | 2.37 M | 7.03 M | 4.64 M | - | 643 K | 1.57 M | 907 K | - | 316 K | 938 K | 282 K | - | - | 376 K | 240 K | - | - | - | - | - | - | - | - | - |
Accounts Payables |
2.81 M | 3.75 M | 5.5 M | 4.52 M | 3.25 M | 5.49 M | 4.62 M | 4.62 M | 5.86 M | 5.86 M | 5.14 M | 5.62 M | 3.51 M | 3.94 M | 5.34 M | 5.94 M | 3 M | 2.64 M | 5.37 M | 5.44 M | 11.3 M | 7.48 M | 10.1 M | 10.8 M | 9.46 M | 8.18 M | 8.61 M | 7.29 M | 9.24 M | 12 M | 8.84 M | 7.24 M | 5.52 M | 5 M | 6.95 M | 5.34 M | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
6.65 M | 5.18 M | 5.06 M | 6.27 M | 6.15 M | 5 M | 4.45 M | 4.45 M | 4.54 M | 4.54 M | 4.52 M | 5.97 M | 5.04 M | 4.33 M | 4.72 M | 3.35 M | 2.36 M | 2.51 M | 2.88 M | 2.86 M | 2.02 M | 2.46 M | 2.8 M | 2.56 M | 1.64 M | 3.95 M | 2.36 M | 2.27 M | 1.48 M | 2.12 M | 2.21 M | 1.81 M | 2.01 M | 2.65 M | 3.23 M | 2.44 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
14.3 M | 12.8 M | 22.1 M | 22 M | 22.8 M | 25 M | 23.2 M | 23.2 M | 23.7 M | 23.7 M | 22.8 M | 21.3 M | 19.8 M | 18.1 M | 16.7 M | 15.6 M | 15.3 M | 15.3 M | 15.6 M | 16.3 M | 16.5 M | 15.2 M | 14.8 M | 13.6 M | 13.2 M | 13.4 M | 12.8 M | 12.6 M | 7.81 M | 5.83 M | 5.01 M | 4.61 M | 4.59 M | 4.42 M | 4.64 M | 4.56 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Quotient Limited, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
$ 23.08 | 1.7 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 29.14 | -3.75 % | $ 326 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
$ 1.1 | 0.46 % | $ 1.4 M | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
- | - | $ 79.8 M | ||
|
DarioHealth Corp.
DRIO
|
$ 11.38 | 1.16 % | $ 323 M | ||
|
DexCom
DXCM
|
$ 70.29 | 8.0 % | $ 27.4 B | ||
|
Celcuity
CELC
|
$ 103.65 | -1.16 % | $ 4.09 B | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
$ 32.89 | 3.09 % | $ 914 M | ||
|
Danaher Corporation
DHR
|
$ 211.14 | -1.74 % | $ 154 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 205.13 | -0.82 % | $ 22.8 B | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
$ 23.24 | 1.18 % | $ 703 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
CareDx, Inc
CDNA
|
$ 19.6 | 2.62 % | $ 1.05 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Interpace Biosciences
IDXG
|
$ 1.85 | - | $ 8.12 M | ||
|
Exact Sciences Corporation
EXAS
|
$ 103.32 | 0.09 % | $ 19.1 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
Lantheus Holdings
LNTH
|
$ 68.71 | -0.02 % | $ 4.75 B | ||
|
Guardant Health
GH
|
$ 104.76 | 1.95 % | $ 12.9 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
National Research Corporation
NRC
|
$ 12.09 | -5.81 % | $ 297 M | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
$ 160.2 | 0.91 % | $ 8.23 B | ||
|
IDEXX Laboratories
IDXX
|
$ 627.58 | 1.68 % | $ 51.8 B | ||
|
Illumina
ILMN
|
$ 115.9 | 1.27 % | $ 18.4 B | ||
|
OPKO Health
OPK
|
$ 1.24 | 2.48 % | $ 861 M | ||
|
IQVIA Holdings
IQV
|
$ 166.72 | -1.27 % | $ 30.2 B | ||
|
Natera
NTRA
|
$ 204.66 | -1.53 % | $ 20.1 B | ||
|
Koninklijke Philips N.V.
PHG
|
$ 31.11 | -0.94 % | $ 20 B | ||
|
Biodesix
BDSX
|
$ 11.55 | 6.6 % | $ 1.5 B | ||
|
Personalis
PSNL
|
$ 8.22 | -2.09 % | $ 487 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 281.39 | 1.13 % | $ 23.6 B | ||
|
ICON Public Limited Company
ICLR
|
$ 95.34 | 19.06 % | $ 7.86 B | ||
|
Biomerica
BMRA
|
$ 2.25 | 4.19 % | $ 5.17 M | ||
|
Bioventus
BVS
|
$ 8.22 | 1.48 % | $ 515 M | ||
|
Medpace Holdings
MEDP
|
$ 429.09 | 3.14 % | $ 12.4 B |